Iressa Drug Failure Deals AstraZeneca Fresh Blow
226836
AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer
161543
Shares in pharmaceutical giants AstraZeneca PLC and GlaxoSmithKline PLC tumbled Friday after a US safety official raised concerns over key drugs sold by the companies.
92784
Pfizer, AstraZeneca and Eli Lilly - each disclosed serious problems with important medicines yesterday, throwing a spotlight on the fact that the $500 billion
191874
Shares in AstraZeneca Plc fell as much as 10 percent on Friday after regulators in the United States and Europe raised safety concerns about the Anglo-Swedish drug maker&#39;s anti-cholesterol treatment Crestor.
481177
Hostile environment prompts root and branch review. Exanta unlikely to win US approval in near future. By Stephen Foley. AstraZeneca, the UK&#39;s number two pharmaceuticals company, has launched a &quot;root and branch
233492
Shares in drug giant AstraZeneca fall after a US medical panel recommends that regulators reject its new drug Exanta.
364661
AstraZeneca PLC&#39;s shares plunged 7.7 percent Friday after a study found that its new lung-cancer drug Iressa failed to improve survival rates among patients.
460971
Will AstraZeneca become the latest casualty in the drug safety debate?
45410
AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer in a major clinical trial, sending its shares down as much as 9.2 percent.
182075
AstraZeneca Plc. said on Wednesday a new study in Japan showed a higher rate of a potentially fatal side effect in patients taking its lung cancer pill Iressa than that demonstrated in an earlier analysis.
410890
AstraZeneca shares have fallen more than 6 percent after a US medical panel recommended regulators reject its anti-clotting pill Exanta, a key product for the company&#39;s future growth.
572824
AstraZeneca PLC said Tuesday that it is withdrawing its application to market its lung cancer drug Iressa in Europe, following findings that the drug failed to prolong survival when compared with a sugar pill.
735577
Shares in OSI Pharmaceuticals (OSIP :Nasdaq - news - research) and Genentech (DNA :Nasdaq - news - research) jumped Friday after AstraZeneca (AZN :NYSE - news - research) said new medical data showed its lung cancer drug Iressa provided no survival
691286
Drug maker AstraZeneca PLC said Friday that the Food and Drug Administration did not approve its orally taken blood thinner Exanta.
556868
Efforts to develop a topical microbicide for use during sex suffered their second failure in a full-scale trial in recent years.
452895
Cape Town - An Indian pharmaceutical company has withdrawn 10 of its generic Aids drugs citing flaws in the research, the Science and Development Network reports.
664897
Astrazeneca Admitted yesterday to an over-optimistic culture within its drug development division as it revealed its recently launched lung cancer pill did not improve patients&#39; life expectancy.